Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients

Roniel Cabrera, Miguel Ararat, Consuelo Soldevilla-Pico, Lisa Dixon, Jen Jung Pan, Roberto Firpi, Victor Machicao, Cynthia Levy, David Nelson, Giuseppe Morelli

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

In transplant recipients transplanted for hepatitis C, presentation of abnormal transaminases can herald the presentation of recurrent hepatitis C, cellular rejection, or both. Given the sometimes ambiguous histology with these 2 entities, the ability to distinguish them is of great importance because misinterpretation can potentially affect graft survival. We used an immune functional assay to help assess the etiology of abnormal liver function test results in liver transplant recipients. Blood samples for the immune functional assay were taken from 42 recipients prospectively at various times post-transplant and compared with clinical and histologic findings. In patients whose liver biopsy showed evidence of cellular rejection, the immune response was noted to be very high, whereas in those with active recurrence of hepatitis C, the immune response was found to be very low. This finding was found to be statistically significant (P < 0.0001). In those patients in whom there was no predominant histologic features suggesting 1 entity over the other, the immune response was higher than in those with aggressive hepatitis C but lower than in those with cellular rejection. In conclusion, these data show the potential utility of the ImmuKnow assay as a means of distinguishing hepatitis C from cellular rejection and its potential usefulness as a marker for outlining the progression of hepatitis C.

Original languageEnglish
Pages (from-to)216-222
Number of pages7
JournalLiver Transplantation
Volume15
Issue number2
DOIs
StatePublished - Jun 29 2009
Externally publishedYes

Fingerprint

Hepatitis C
Transplants
Liver
Liver Function Tests
Graft Survival
Transaminases
Cellular Immunity
Histology
Biopsy
Recurrence

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

Cabrera, R., Ararat, M., Soldevilla-Pico, C., Dixon, L., Pan, J. J., Firpi, R., ... Morelli, G. (2009). Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transplantation, 15(2), 216-222. https://doi.org/10.1002/lt.21666

Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. / Cabrera, Roniel; Ararat, Miguel; Soldevilla-Pico, Consuelo; Dixon, Lisa; Pan, Jen Jung; Firpi, Roberto; Machicao, Victor; Levy, Cynthia; Nelson, David; Morelli, Giuseppe.

In: Liver Transplantation, Vol. 15, No. 2, 29.06.2009, p. 216-222.

Research output: Contribution to journalArticle

Cabrera, R, Ararat, M, Soldevilla-Pico, C, Dixon, L, Pan, JJ, Firpi, R, Machicao, V, Levy, C, Nelson, D & Morelli, G 2009, 'Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients', Liver Transplantation, vol. 15, no. 2, pp. 216-222. https://doi.org/10.1002/lt.21666
Cabrera, Roniel ; Ararat, Miguel ; Soldevilla-Pico, Consuelo ; Dixon, Lisa ; Pan, Jen Jung ; Firpi, Roberto ; Machicao, Victor ; Levy, Cynthia ; Nelson, David ; Morelli, Giuseppe. / Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. In: Liver Transplantation. 2009 ; Vol. 15, No. 2. pp. 216-222.
@article{a1a84eef9892497184b096ca49e469c6,
title = "Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients",
abstract = "In transplant recipients transplanted for hepatitis C, presentation of abnormal transaminases can herald the presentation of recurrent hepatitis C, cellular rejection, or both. Given the sometimes ambiguous histology with these 2 entities, the ability to distinguish them is of great importance because misinterpretation can potentially affect graft survival. We used an immune functional assay to help assess the etiology of abnormal liver function test results in liver transplant recipients. Blood samples for the immune functional assay were taken from 42 recipients prospectively at various times post-transplant and compared with clinical and histologic findings. In patients whose liver biopsy showed evidence of cellular rejection, the immune response was noted to be very high, whereas in those with active recurrence of hepatitis C, the immune response was found to be very low. This finding was found to be statistically significant (P < 0.0001). In those patients in whom there was no predominant histologic features suggesting 1 entity over the other, the immune response was higher than in those with aggressive hepatitis C but lower than in those with cellular rejection. In conclusion, these data show the potential utility of the ImmuKnow assay as a means of distinguishing hepatitis C from cellular rejection and its potential usefulness as a marker for outlining the progression of hepatitis C.",
author = "Roniel Cabrera and Miguel Ararat and Consuelo Soldevilla-Pico and Lisa Dixon and Pan, {Jen Jung} and Roberto Firpi and Victor Machicao and Cynthia Levy and David Nelson and Giuseppe Morelli",
year = "2009",
month = "6",
day = "29",
doi = "10.1002/lt.21666",
language = "English",
volume = "15",
pages = "216--222",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients

AU - Cabrera, Roniel

AU - Ararat, Miguel

AU - Soldevilla-Pico, Consuelo

AU - Dixon, Lisa

AU - Pan, Jen Jung

AU - Firpi, Roberto

AU - Machicao, Victor

AU - Levy, Cynthia

AU - Nelson, David

AU - Morelli, Giuseppe

PY - 2009/6/29

Y1 - 2009/6/29

N2 - In transplant recipients transplanted for hepatitis C, presentation of abnormal transaminases can herald the presentation of recurrent hepatitis C, cellular rejection, or both. Given the sometimes ambiguous histology with these 2 entities, the ability to distinguish them is of great importance because misinterpretation can potentially affect graft survival. We used an immune functional assay to help assess the etiology of abnormal liver function test results in liver transplant recipients. Blood samples for the immune functional assay were taken from 42 recipients prospectively at various times post-transplant and compared with clinical and histologic findings. In patients whose liver biopsy showed evidence of cellular rejection, the immune response was noted to be very high, whereas in those with active recurrence of hepatitis C, the immune response was found to be very low. This finding was found to be statistically significant (P < 0.0001). In those patients in whom there was no predominant histologic features suggesting 1 entity over the other, the immune response was higher than in those with aggressive hepatitis C but lower than in those with cellular rejection. In conclusion, these data show the potential utility of the ImmuKnow assay as a means of distinguishing hepatitis C from cellular rejection and its potential usefulness as a marker for outlining the progression of hepatitis C.

AB - In transplant recipients transplanted for hepatitis C, presentation of abnormal transaminases can herald the presentation of recurrent hepatitis C, cellular rejection, or both. Given the sometimes ambiguous histology with these 2 entities, the ability to distinguish them is of great importance because misinterpretation can potentially affect graft survival. We used an immune functional assay to help assess the etiology of abnormal liver function test results in liver transplant recipients. Blood samples for the immune functional assay were taken from 42 recipients prospectively at various times post-transplant and compared with clinical and histologic findings. In patients whose liver biopsy showed evidence of cellular rejection, the immune response was noted to be very high, whereas in those with active recurrence of hepatitis C, the immune response was found to be very low. This finding was found to be statistically significant (P < 0.0001). In those patients in whom there was no predominant histologic features suggesting 1 entity over the other, the immune response was higher than in those with aggressive hepatitis C but lower than in those with cellular rejection. In conclusion, these data show the potential utility of the ImmuKnow assay as a means of distinguishing hepatitis C from cellular rejection and its potential usefulness as a marker for outlining the progression of hepatitis C.

UR - http://www.scopus.com/inward/record.url?scp=67649172198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649172198&partnerID=8YFLogxK

U2 - 10.1002/lt.21666

DO - 10.1002/lt.21666

M3 - Article

VL - 15

SP - 216

EP - 222

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 2

ER -